New publication📝Real-world data published in Acta Haematologica show ponatinib achieved 60.7% CR in R/R Ph+ ALL, but 2-year OS remained 29.5%, highlighting need for combination strategies. Learn more: loom.ly/tDWx0XE #ALLsm #leusm #MedNews #MedEd

New publication 📝 Results from a phase I/II study, published in Blood Journals Portfolio, show WU-CART-007 at the RP2D achieved an ORR of 90.9% with a manageable safety profile in patients with relapsed/refractory T-ALL or LBL. Learn more: loom.ly/EvtL7yw #ALLsm #MedEd

The ALL Hub newsletter provides healthcare professionals with up-to-date global advances in acute lymphoblastic leukemia relating to its classification, diagnosis, treatment, and management. View a previous newsletter: loom.ly/1YNtEtA #allsm #leusm

New publication📝Data, published in AmericanJournalofHematology, show allogeneic HSCT in CR2 in AYAs with ALL achieved 3-year OS of 53% and PFS of 46%. MRD status and comorbidities were key predictors of outcomes. Learn more: loom.ly/4eZUbvc #ALLsm #leusm #MedNews #MedEd

New publication 📝 A real-world study, published in Oxford Journals, found dasatinib was associated with new safety signals and off-label use in pediatric patients with malignancies, including Ph+ #ALL and Ph+ CML. Learn more: loom.ly/-UnsUT8 #leusm #MedNews #MedEd

New publication📝 EHA/ELN panel recommendations published in @haematologica provide guidance for establishing standardized criteria for reporting blast percentage to ensure uniform response and relapse assessment in acute leukemias. Learn more: loom.ly/GxxSEc8 #ALL

New publication📝Real-world data, published in Clinical Lymphoma Myeloma and Leukemia, show CR was achieved in 96.9% of adults with de novo Ph+ #ALL treated with flumatinib + chemotherapy. Learn more: loom.ly/Yh4qiGw #leusm #MedNews #MedEd

New publication📝US consensus panel recommendations, published in AmericanJournalofHematology, identify and address the barriers associated with administering asparaginase-based therapy in AYA patients with ALL/LBL. Learn more: loom.ly/BkjuPcM #ALLsm #leusm #MedNews #MedEd

New publication 📝 Comparison of outcomes from GRAALL-2014 vs 2005, published in Blood Journals Portfolio, found age-adapted treatment strategies improved outcomes in patients aged 18–59 years with Ph-negative ALL. Learn more: loom.ly/d5DnDLU #ALLsm #leusm #MedNews #MedEd

Would you like to bookmark content, select your specific areas of interest, and view content recommended for you? Enter your email address to create an account: loom.ly/KbsdLYA #allsm #leusm

🚨 News 🚨 U.S. FDA granted final approval for an abbreviated new drug application for generic dasatinib tablets in multiple doses (20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg) for the treatment of Ph+ #ALL and CML. Read more: loom.ly/fNWjMHM #leusm #MedNews #MedEd

🚨 News 🚨 U.S. FDA grants fast track designation for 4A10, a monoclonal antibody targeting IL-7Rα; CD127, for the treatment of patients with relapsed or refractory #ALL. Read more: loom.ly/0aMKbOw #leusm #MedNews #MedEd

New publication 📝 Results from a phase I trial, published in The Lancet Haematology, show that anti-CD19 CAR T cells expressing IL-10 (META 10-19) has a manageable safety profile in patients with R/R B-ALL. Learn more: loom.ly/YTaO8ik #ALLsm #MedNews

New publication 📝 Real-world data from the CIBMTR registry, published in Blood Advances, show tisa-cel achieved a best ORR of 86% with improved safety in pediatric and young adult patients with R/R B-ALL. Learn more: loom.ly/rG6CkQ8 #ALLsm #leusm #MedNews #MedEd

New publication 📝 A retrospective study, published in the Annals of Hematology, found that asparaginase discontinuation led to higher relapse risk in pediatric patients with ALL; 6-year CIR, 27.5% vs 14.0% (p = 0.01). Learn more: loom.ly/y2SJIvk #ALLsm #leusm #MedEd

New publication📝 Results from Alliance A041703 Cohort 1, published in Journal of Clinical Oncology, show InO followed by blinatumomab achieved a 1-year EFS rate of 75% and OS rate of 85% in older patients with Ph-negative B-ALL. Learn more: loom.ly/xZmYxgs #ALLsm #leusm #MedNews #MedEd

Results from the FELIX trial demonstrated a correlation between the depth of MRD-negative remission and clinical outcomes in adults with R/R B-ALL treated with obecabtagene autoleucel. #ALLsm #leusm #MedEd loom.ly/pJIuFxM

🚨 News 🚨NICE has recommended obecabtagene autoleucel, a next-generation CAR T-cell therapy, for routine use in England and Wales for adult patients (≥26 years) with R/R B-cell ALL. Read more: loom.ly/ufIOH0I #ALLsm #leusm #MedNews #MedEd

New expert opinion video Carmelo Rizzari discusses how therapeutic drug monitoring and premedication can be applied in clinical practice to optimize pegaspargase treatment in patients with ALL. loom.ly/C6s9hc4 #ALLsm #leusm #MedNews #MedEd Carmelo Rizzari

New publication📝 A retrospective analysis, published in Pediatric Blood & Cancer, shows InO achieved an ORR of 77.8% in children and young adults with R/R B-ALL post-CD19 CAR T-cell therapy. Learn more: loom.ly/y2SJIvk #ALLsm #leusm #MedNews #MedEd